ELN heating up, AMLN should be heating up, DNDN, ARNA maintaining status quo

ELN
With the latest J&J cash infusion and partnership, ELN now has all the tools to succeed, money & strong pharma support / validation of its pipeline... Two clouds remain, the PML issue, although with no real news or development, continue to be used relentlessly by the short cabal to drive the PPS down every time a case is reported... I don't know how long this will be allowed to go on, as the FDA allows for 1/1000 case to occur and with all the reported case we are well below that rate. The second cloud is the management strength, let's hope they don't waste the new opportunity they've been given. The current stock price does not reflect the new found strength, as a lot of the risk has been removed from stock. I am looking for the low teens in the near future and selling puts to accumulate.

AMLN

What a disappointment this stock has been this second time around! Never, has a management team done so little with so much. They have money, an incredible pipeline, two first and best in class drugs and yet they don't succeed. The root of the problem is the management team and culture that has permeated this company since the beginning. They were essentially a good development team, then after their drugs got approved, essentially did not and still have not changed their mode of operation. They have not been able to successfully switch from being a development biotech to a pharma with products to sell. They have hired poorly and their current CEO is a big part of the problem.. He appears to be a hard worker, but exudes little confidence and is a horrible communicator... Anyway, enough ramblings... What to do?
I am staying put with my holdings, the upside is still great, but I probably will exit in the mid 20's if the pps gets there. The catalyst for a move up in the short terms are..
- A rejection of ligaritude ( a byetta competing drug ) by the FDA.. The FDA should reject or at minimum give them an approvable letter, but you will never know with the FDA as they are for the most part a captured and political agency. Note that Ligar has just been approved in Europe.
- Monotherapy for byetta. Its a decision that's more then 6 months behind schedule. I do not understand why the FDA has not responded yet, scratch that, I do understand, see above comments.
- Clarification of the Byetta label and the removal of the pancreatitis cloud from Byetta. Again, the FDA botched that one. They issued a safety warning for byetta for pancreatitis when the rate of occurrence is at worse equal to the diabetic population. The reality is even more perplexing, since byetta is prescribed to obese patient because of its weight loss proprety, the byetta population is even more prone to pancreatitis. So, the data seems to indicate that Byetta actually decreases the rate of pancreatitis... But go figure our FDA, they issue a warning, what a bunch of boobs!!!

But ultimately, its the role of management to play whatever game the FDA needs them to play to get these things done... And this management team just does not know how to play the game. The recent Icahn and eastbourne BOD wins, have yet to translate to any material changes .

A note of caution. A ligaritude approval could eviscerate the byetta scrips and send the PPS back to the single digits.

AMLN, ELN, DNDN - Brief updates

AMLN
Essentially, I am staying put and really not adding anymore shares. Right now, I am not giving much "weight" pun intended to the obesity pipeline. My reasoning is that Amylin with current management and its approach to marketing and sales, have not demonstrated that they can have a blockbuster injectable when going against inferior oral drugs... I will turn on a dime if they start doing better... Maybe the new VP can turn it around... But certainly based on side effect and efficacy, Amylin obesity drugs should dominate... But then again so should symlin and byetta... So until management can show me what they can do in sales with Byetta and LAR, I am ignoring the obesity potential.
DNDN
Nothing new to report. Same strategy as previously posted.
ELN
I have increased my activities in ELN, sold more puts with the intent to add to my initial shares... The more I learn about Tysabri and the positive impact it has on MS patients (see link: http://www.youtube.com/watch?v=1JXDLHcWyws ), the more I think this stock is very undervalued and certainly could do a 4-5x from here. The problem is that I never buy all the shares I want to own in a company all at once... I build the investment in stages, as I learn about the company and get more comfortable with the various forces that affect the share price. Typically I build the position in 4 or 5 stages. I have done stage I with ELN, but this time, I might not have time to add more... The stock jumped a bit today on news that Bristol-Myer, might be interested in buying a piece of ELN. So I probably wont be adding shares by selling puts, I had the June $6... I will have to decide if I should just buy stage II in the open market.